SKYE SKYE BIOSCIENCE INC

Skye Bioscience to Participate in SXSW Session on Obesity

Skye Bioscience to Participate in SXSW Session on Obesity

SAN DIEGO, Feb. 24, 2025 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (Nasdaq: SKYE) (“Skye”), a clinical-stage biopharmaceutical company focused on unlocking new therapeutic pathways for obesity and other metabolic health disorders, is pleased to announce the participation of Punit Dhillon, Chief Executive Officer, in a South by Southwest panel session exploring the future of obesity management beyond GLP-1 drugs.

SXSW Conference Panel Session: "Weighing in on Weight Loss Medicine"

  • Focus: The
  • Date: Monday, March 10, 2025
  • Time: 10:00 AM - 11:00 AM CT
  • Location: Austin, TX

SXSW is renowned for converging technology, film, music, education, and culture. Known for fostering innovation and collaboration, SXSW provides a global platform for thought leaders, industry experts, and visionaries to share insights, explore emerging trends, and drive meaningful conversations. Its dedicated tracks on health and medtech spotlight groundbreaking advancements and transformative ideas shaping the future of life sciences.

About Skye Bioscience

Skye is focused on unlocking new therapeutic pathways for metabolic health through the development of next-generation molecules that modulate G-protein coupled receptors. Skye's strategy leverages biologic targets with substantial human proof of mechanism for the development of first-in-class therapeutics with clinical and commercial differentiation. Skye is conducting a Phase 2 clinical trial (ClinicalTrials.gov: NCT06577090) in obesity for nimacimab, a negative allosteric modulating antibody that peripherally inhibits CB1. This study is also assessing the combination of nimacimab and a GLP-1R agonist (Wegovy®). For more information, please visit: Connect with us on X and LinkedIn.

CONTACTS

Investor Relations



(858) 410-0266

LifeSci Advisors, Mike Moyer



(617) 308-4306

Media Inquiries

LifeSci Communications, Michael Fitzhugh



(628) 234-3889



EN
24/02/2025

Underlying

SKYESKYE BIOSCIENCE INC

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on SKYE BIOSCIENCE INC

 PRESS RELEASE
Free
SKYE SKYE BIOSCIENCE...

Skye Bioscience to Participate in Upcoming Investment Conferences

Skye Bioscience to Participate in Upcoming Investment Conferences SAN DIEGO, May 22, 2025 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (Nasdaq: SKYE) (“Skye”), a clinical-stage biotechnology company focused on unlocking new therapeutic pathways for obesity and other metabolic health disorders, today announced that it will participate in the following upcoming healthcare conferences: Investment Conferences Jefferies Global Healthcare Conference (New York)   Presentation Thursday, June 5, 9:20 AM ET + 1x1 meetings Sachs European BioPharma Obe...

May 22, 2025 1 EN
 PRESS RELEASE
Free
SKYE SKYE BIOSCIENCE...

Skye Bioscience Establishes Partnership with Arecor Therapeutics to De...

Skye Bioscience Establishes Partnership with Arecor Therapeutics to Develop Enhanced Formulation of Obesity Candidate Nimacimab Proprietary formulation technology being applied to potentially enhance properties of nimacimab SAN DIEGO, May 19, 2025 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (Nasdaq: SKYE) (“Skye”), a clinical-stage biotechnology company focused on unlocking new therapeutic pathways for obesity and other metabolic health disorders, today announced a formulation development collaboration with Arecor Therapeutics plc (AIM: AREC), the biopharmaceutical company advancing today...

May 19, 2025 1 EN
 PRESS RELEASE
Free
SKYE SKYE BIOSCIENCE...

Skye Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Skye Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) SAN DIEGO, May 13, 2025 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (Nasdaq: SKYE) (“Skye”), a clinical-stage biopharmaceutical company focused on unlocking new therapeutic pathways for metabolic health, today announced that on May 7, 2025, the Board of Directors granted a non-qualified stock option award to purchase 100,000 shares of its common stock to one new non-executive employee under the Company’s Amended and Restated 2024 Inducement Equity Incentive Plan (the “2024 Inducement Plan”). The stock options were granted ...

May 13, 2025 1 EN
 PRESS RELEASE
Free
SKYE SKYE BIOSCIENCE...

Skye Bioscience Clinical Model Demonstrating Necessity of Peripheral C...

Skye Bioscience Clinical Model Demonstrating Necessity of Peripheral CB1 Inhibition for Weight Loss Presented at European Congress on Obesity • This model demonstrates that central inhibition of CB1 is not required for weight loss • Anti-CB1 inhibiting antibody, nimacimab, showed greatest peripheral restriction compared with monlunabant and rimonabant, small molecule-based CB1 inhibitors, which both exhibited increasing dose-dependent brain penetration • This model predicts nimacimab’s potentially superior therapeutic index, which is dependent on minimal brain exposure while maintaining s...

May 13, 2025 1 EN
 PRESS RELEASE
Free
SKYE SKYE BIOSCIENCE...

Skye Bioscience Reports First Quarter 2025 Results and Highlights Nima...

Skye Bioscience Reports First Quarter 2025 Results and Highlights Nimacimab Differentiation in Obesity Nimacimab in combination with tirzepatide improves weight loss effect over tirzepatide alone, and shows comparable weight loss to monlunabant and tirzepatide alone in preclinical diet-induced obesity modelIn vitro data reported from new preclinical study highlights superior potency of peripherally restricted CB1 inhibitor, nimacimab, versus monlunabant when tested under pathological levels of CB1 agonistsExpanded preclinical study data to be presented at ADA in June 2025Top-line data reado...

May 8, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch